TITLE

Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors

AUTHOR(S)
Takano, Shingo; Kato, Yukinari; Yamamoto, Tetsuya; Kaneko, Mika; Ishikawa, Eiichi; Tsujimoto, Yuta; Matsuda, Masahide; Nakai, Kei; Yanagiya, Ryo; Morita, Shunpei; Tsuboi, Koji; Matsumura, Akira
PUB. DATE
July 2012
SOURCE
Journal of Neuro-Oncology;Jul2012, Vol. 108 Issue 3, p361
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Isocitrate dehydrogenase 1 (IDH1) mutations, which are early and frequent genetic alterations in astrocytomas, oligodendrogliomas, oligoastrocytomas, and secondary glioblastomas, are specific to arginine 132 (R132). Recently, we established monoclonal antibodies (mAbs) against IDH1 mutations: anti-IDH1-R132H and anti-IDH1-R132S. However, the importance of immunohistochemistry using the combination of those mAbs has not been elucidated. For this study, 164 cases of glioma were evaluated immunohistochemically for IDH1 mutations (R132H and R132S) using anti-IDH1 mAbs (HMab-1 and SMab-1). IDH1 mutation was detected, respectively, in 9.7%, 63.6%, 51.7%, and 77.8% of primary grade IV, secondary grade IV, grade III, and grade II gliomas. For each grade of glioma, prognostic factors for progression-free survival and overall survival were evaluated using clinical and pathological parameters in addition to IDH1 immunohistochemistry. IDH1 mutation, p53 overexpression, and internexin expression, as evaluated using immunohistochemistry with clinical parameters such as degree of surgical removal and preoperative Karnofsky Performance Status (KPS), might be of greater prognostic significance than histological grading alone in grade III as well as IDH1 mutation in grade IV gliomas.
ACCESSION #
76350894

 

Related Articles

  • Glioblastoma with oligodendroglial component represents a subgroup of glioblastoma with high prevalence of IDH1 mutation and association with younger age. Ha, Sang; Kang, So; Do, In-Gu; Suh, Yeon-Lim // Journal of Neuro-Oncology;May2013, Vol. 112 Issue 3, p439 

    Glioblastoma with an oligodendroglial component (GBMO) is recognized as a subgroup of glioblastoma (GBM); however, the molecular and clinicopathological characteristics of GBMO are obscure. We evaluated the methylation status of MGMT, IDH1/2 mutation, deletions of 1p and 19q and expression of...

  • Establishment of a Multi-Specific Monoclonal Antibody MsMab-1 Recognizing Both IDH1 and IDH2 Mutations. Kaneko, Mika Kato; Ogasawara, Satoshi; Kato, Yukinari // Tohoku Journal of Experimental Medicine;Jun2013, Vol. 230 Issue 2, p103 

    Mutations of isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) have been reported in gliomas, cartilaginous tumors, and acute myeloid leukemias. IDH mutations are specific to a single codon in the conserved and functionally important arginine 132 residue (R132) of IDH1 or...

  • p53 protein alterations in adult astrocytic tumors and oligodendrogliomas. Nayak, Anupma; Ralte, Angela Mercy; Sharma, Mehar Chand; Singh, Varinder Paul; Mahapatra, Ashok Kumar; Mehta, Veer Singh; Sarkar, Chitra // Neurology India;Jun2004, Vol. 52 Issue 2, p228 

    Background: p53 is a tumor suppressor gene implicated in the genesis of a variety of malignancies including brain tumors. Overexpression of the p53 protein is often used as a surrogate indicator of alterations in the p53 gene. Aims: In this study, data is presented on p53 protein expression in...

  • IDH1 mutation is prognostic for diffuse astrocytoma but not low-grade oligodendrogliomas in patients not treated with early radiotherapy. Iwadate, Yasuo; Matsutani, Tomoo; Hirono, Seiichiro; Ikegami, Shiro; Shinozaki, Natsuki; Saeki, Naokatsu // Journal of Neuro-Oncology;Sep2015, Vol. 124 Issue 3, p493 

    Despite accumulating knowledge regarding molecular backgrounds, the optimal management strategy for low-grade gliomas remains controversial. One reason is the marked heterogeneity in the clinical course. To establish an accurate subclassification of low-grade gliomas, we retrospectively...

  • No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas. Ahmadi, Rezvan; Stockhammer, Florian; Becker, Natalia; Hohlen, Katarina; Misch, Martin; Christians, Arne; Dictus, Christine; Herold-Mende, Christel; Capper, David; Unterberg, Andreas; Deimling, Andreas; Wick, Wolfgang; Hartmann, Christian // Journal of Neuro-Oncology;Aug2012, Vol. 109 Issue 1, p15 

    Mutations in the gene encoding isocitrate dehydrogenase 1 ( IDH1) have been identified in approximately 70-80 % of astrocytomas and oligodendrogliomas of WHO grades II and III, and in secondary glioblastomas. In addition, a low incidence of IDH2 mutations has been detected in these tumors, and...

  • C-terminally truncated form of αB-crystallin is associated with IDH1 R132H mutation in anaplastic astrocytoma. Avliyakulov, Nuraly; Rajavel, Kavitha; Le, Khanh; Guo, Lea; Mirsadraei, Leili; Yong, William; Liau, Linda; Li, Sichen; Lai, Albert; Nghiemphu, Phioanh; Cloughesy, Timothy; Linetsky, Michael; Haykinson, Michael; Pope, Whitney // Journal of Neuro-Oncology;Mar2014, Vol. 117 Issue 1, p53 

    Malignant gliomas are the most common human primary brain tumors. Point mutation of amino acid arginine 132 to histidine (R132H) in the IDH1 protein leads to an enzymatic gain-of-function and is thought to promote gliomagenesis. Little is known about the downstream effects of the IDH1 mutation...

  • 1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth. Gozé, Catherine; Bezzina, Charlotte; Gozé, Eric; Rigau, Valérie; Maudelonde, Thierry; Bauchet, Luc; Duffau, Hugues // Journal of Neuro-Oncology;May2012, Vol. 108 Issue 1, p69 

    Mutations at the codon 132 in the isocitrate dehydrogenase 1 ( IDH1) gene occur early, with a high frequency, in World Health Organization (WHO) grade II gliomas. We investigated the impact of IDH1 mutations on spontaneous glioma growth rate, known to be an early prognostic factor.The mean tumor...

  • p53 protein expression and genetic mutation in two primary cell types in pulmonary sclerosing haemangioma. Wang, Y.; Dai, S.-D.; Qi, F.-J.; Xu, H.-T.; Wang, E.-H. // Journal of Clinical Pathology;Feb2008, Vol. 61 Issue 2, p192 

    Aims: To investigate the significance of p53 protein expression and genetic mutations in two primary cell types in pulmonary sclerosing haemangioma (PSH). Methods: p53 protein expression in polygonal cells and cuboidal cells in 19 patients with PSH was detected using immunohistochemistry. The...

  • Immunoexpression of Ultraviolet Photoproducts and p53 Mutation Analysis in Atypical Fibroxanthoma and Superficial Malignant Fibrous Histiocytoma. Sakamoto, Akio; Oda, Yoshinao; Itakura, Eijun; Oshiro, Yumi; Nikaido, Osamu; Iwamoto, Yukihide; Tsuneyoshi, Masazumi // Modern Pathology;Jun2001, Vol. 14 Issue 6, p581 

    p53 mutation is one of the major results of ultraviolet (UV) radiation. UV photoproducts of cyclobutane pyrimidine dimers (CPDs) and pyrimidine-pyrimidone (6-4) photoproducts (64PPs) also play an important role in skin cancer development. Atypical fibroxanthoma (AFX), which mimics malignant...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics